Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="articleColumn">Gapping up<p><strong>Gapping up<br/> In reaction to strong earnings/guidance</strong>:</p><ul><li><strong>HTBX</strong> +25.8%, <strong>TENX</strong> +18.4%, <strong>CMCM</strong> +1.9%, <strong>FRAN</strong> +1.7%</li></ul><p><strong>Select EU financial related names showing strength</strong>:</p><ul><li><strong>BCS</strong> +3.3%, <strong>SAN</strong> +3.2%, <strong>ING</strong> +2.5%, <strong>BBVA</strong> +2.5%, <strong>LYG</strong> +1.7%, <strong>CS</strong> +1.6%, <strong>RBS</strong> +1.4%, <strong>PUK</strong> +1.1%, <strong>HSBC</strong> +1%</li></ul><p><strong>Select oil/gas related names showing strength</strong>:</p><ul><li><strong>WFT</strong> +2.1%, <strong>TNP</strong> +1.4%, <strong>STO</strong> +1.2%, <strong>TOT</strong> +1%, <strong>WLL</strong> +0.9%, <strong>RIG</strong> +0.8%, <strong>BP</strong> +0.7%, <strong>RDS.A</strong> +0.7%</li></ul><p><strong>Other news</strong>:</p><ul><li><strong>PTIE</strong> +48.5% (receives positive regulatory guidance from FDA for REMOXY)</li><li><strong>HTBX</strong> +23.7% (announces the latest results of its ongoing Phase 2 clinical trial of HS-110 in combination with Opdivo for the treatment of non-small cell lung cancer)</li><li><strong>CBK</strong> +13.3% (CEO Joel Waller discloses the purchase of 20k shares at $1.26)</li><li><strong>WCST</strong> +0.9% (Enters into a Capital Increase Agreement with Guizhou Sun Seven Stars Technology Company Limited)</li></ul><p><strong>Analyst comments</strong>:</p><ul><li><strong>WMGI</strong> +2.7% (upgraded to Buy from Neutral at Northcoast)</li><li><strong>FCX</strong> +2.4% (upgraded to Hold from Sell at Deutsche Bank)</li><li><strong>CCL</strong> +1% (upgraded to Outperform from Market Perform at William Blair)</li><li><strong>PAAS</strong> +0.9% (upgraded to Outperform at RBC Capital Mkts)</li><li><strong>BWXT</strong> +0.9% (upgraded to Buy from Neutral at BofA/Merrill)</li><li><strong>FB</strong> +0.7% (upgraded to Buy from Neutral at BTIG Research)</li></ul></td> </tr></table>"